Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics, Inc. (Nasdaq: KROS) announced preliminary results from its Phase 2 trial of KER-050 for treating anemia and thrombocytopenia in patients with myelodysplastic syndromes. As of May 14, 2021, twelve patients were treated, with five achieving significant hematological endpoints. The drug was well tolerated, with no serious drug-related adverse events reported. Based on the results, Keros will extend the trial duration to up to two years and initiate further trial phases. A conference call is scheduled for June 23, 2021, to discuss these findings.

Keros Therapeutics (KROS) presented significant preclinical data at the EHA2021 Virtual Congress, highlighting the efficacy of ALK2 inhibition and the novel therapy KER-050. Studies showed that ALK2 inhibition reduced hepcidin levels and improved iron homeostasis in models of anemia and iron overload. KER-050 exhibited rapid and sustainable effects on erythropoiesis and increased erythropoietin levels, supporting its potential as a treatment for myelodysplastic syndromes and myelofibrosis. Results indicate promising therapeutic avenues for conditions related to elevated hepcidin.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 1 at 2:00 PM EST. The presentation will be available via a live webcast and will also be archived on Keros' Investors section for 90 days. Keros focuses on developing innovative treatments for hematological and musculoskeletal disorders, with key product candidates including KER-050 for cytopenias, KER-047 for anemia from iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.

Keros Therapeutics, Inc. (Nasdaq: KROS) announced the issuance of U.S. Patent No. 11,013,785, a foundational patent for novel therapeutic proteins, including KER-050. This patent is critical for Keros' wholly-owned internal programs and extends patent protection until at least November 2037. KER-050 is designed to treat cytopenias like anemia in patients with myelodysplastic syndromes and myelofibrosis. Keros plans to enhance its patent portfolio to support its expanding pipeline of hematological and musculoskeletal treatments.

Keros Therapeutics (Nasdaq: KROS) announced promising results from a preclinical study of KER-012 targeting pulmonary arterial hypertension (PAH) at the American Thoracic Society International Conference. The study demonstrated that KER-012 prevented markers of inflammation, fibrosis, and vascular remodeling in a rodent PAH model. Notably, the treatment reduced right ventricle and arterial wall thickness without increasing red blood cell counts, indicating potential for safe treatment of PAH. KER-012 could also enhance signaling pathways involved in bone disorders and PAH.

Keros Therapeutics (Nasdaq: KROS) announced the presentation of four abstracts from its KER-050 and ALK2 programs at the upcoming 26th Annual Congress of the European Hematology Association, taking place virtually from June 9-17, 2021. Findings include promising preclinical data on KER-050's ability to promote red blood cell production, relevant for conditions like myelodysplastic syndromes. The company is on track to report initial data from its Phase 2 clinical trial of KER-050 by the end of June 2021, solidifying its commitment to addressing hematological disorders.

Keros Therapeutics, Inc. (Nasdaq: KROS) reported a net loss of $15.9 million for Q1 2021, up from $11.9 million in Q1 2020, primarily due to increased research and development efforts. R&D expenses rose to $11.5 million, driven by activities related to KER-012 and higher personnel costs. General and administrative costs also increased to $4.3 million, reflecting organizational growth. Cash reserves stood at $255.2 million, expected to fund operations through Q4 2023. The company is advancing various clinical trials, including a Phase 2 trial of KER-050, with initial results anticipated mid-2021.

Keros Therapeutics (KROS) announced a business update and 2020 financial results, highlighting significant progress in clinical trials and a successful public offering. The fourth quarter net loss was $10.7 million, with a total loss of $45.4 million for the year, up from $12.3 million in 2019. R&D expenses totaled $9.7 million for Q4 and $33.9 million for 2020, reflecting increased activities. As of December 31, 2020, cash and equivalents stood at $265.9 million, securing operational funding into Q4 2023. Upcoming milestones include new trials for KER-050 and KER-047.

Keros Therapeutics (Nasdaq: KROS) presented preclinical results of KER-050 and its ALK2 inhibitor program at the ESH Translational Research E-Conference. The data supports a rapid hematological response and durable effects observed during Phase 1 trials, indicating potential for treating anemia due to ineffective erythropoiesis, particularly in myelodysplastic syndromes and myelofibrosis. Notable increases in red blood cells (7%) and hemoglobin (6.7%) were observed in mice after treatment with RKER-050, demonstrating promise in addressing hepcidin-mediated anemia and enhancing iron availability.